The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics

The current pandemic of coronavirus disease (COVID-19) caused by SARS-CoV-2 is a significant global health challenge. A recent study by Carvelli and colleagues now demonstrates the involvement of complement C5a and its receptor C5aR1 in disease progression and suggests that blockade of the C5a-C5aR1...

Descripción completa

Detalles Bibliográficos
Autores principales: Woodruff, Trent M., Shukla, Arun K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Ltd. 2020
Materias:
Spotlight
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510552/
https://www.ncbi.nlm.nih.gov/pubmed/33023856
http://dx.doi.org/10.1016/j.it.2020.09.008
_version_ 1783585812048248832
author Woodruff, Trent M.
Shukla, Arun K.
author_facet Woodruff, Trent M.
Shukla, Arun K.
author_sort Woodruff, Trent M.
collection PubMed
description The current pandemic of coronavirus disease (COVID-19) caused by SARS-CoV-2 is a significant global health challenge. A recent study by Carvelli and colleagues now demonstrates the involvement of complement C5a and its receptor C5aR1 in disease progression and suggests that blockade of the C5a-C5aR1 axis may represent a potential therapeutic strategy against COVID-19.
format Online
Article
Text
id pubmed-7510552
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-75105522020-09-24 The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics Woodruff, Trent M. Shukla, Arun K. Trends Immunol Spotlight The current pandemic of coronavirus disease (COVID-19) caused by SARS-CoV-2 is a significant global health challenge. A recent study by Carvelli and colleagues now demonstrates the involvement of complement C5a and its receptor C5aR1 in disease progression and suggests that blockade of the C5a-C5aR1 axis may represent a potential therapeutic strategy against COVID-19. Elsevier Ltd. 2020-11 2020-09-23 /pmc/articles/PMC7510552/ /pubmed/33023856 http://dx.doi.org/10.1016/j.it.2020.09.008 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Spotlight
Woodruff, Trent M.
Shukla, Arun K.
The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics
title The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics
title_full The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics
title_fullStr The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics
title_full_unstemmed The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics
title_short The Complement C5a-C5aR1 GPCR Axis in COVID-19 Therapeutics
title_sort complement c5a-c5ar1 gpcr axis in covid-19 therapeutics
topic Spotlight
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7510552/
https://www.ncbi.nlm.nih.gov/pubmed/33023856
http://dx.doi.org/10.1016/j.it.2020.09.008
work_keys_str_mv AT woodrufftrentm thecomplementc5ac5ar1gpcraxisincovid19therapeutics
AT shuklaarunk thecomplementc5ac5ar1gpcraxisincovid19therapeutics
AT woodrufftrentm complementc5ac5ar1gpcraxisincovid19therapeutics
AT shuklaarunk complementc5ac5ar1gpcraxisincovid19therapeutics

Ejemplares similares